Fluticasone Propionate And Salmeterol Powder, Metered
Product Images NDC 50090-3271

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 50090-3271). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fp Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 1)

Chemical structure diagram of fluticasone propionate, one of the active ingredients in Fluticasone Propionate and Salmeterol inhalation powder.*

FDA Label Image

Figure 8 (Fluticasone Propionate Salmeterol Inhalation Powde 10)

Line graph depicting mean change in FEV1 (L) over 12 hours following administration of AIRDUO RESPICLICK and Fluticasone Propionate MDPI at varying dosages, compared to placebo. The graph tracks changes from baseline at day 1 and week 12, showing response patterns over time for different treatment groups.*

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 11)

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 12)

FDA Label Image

Figurr A (Fluticasone Propionate Salmeterol Inhalation Powde 13)

An instructional diagram showing a metered dose inhaler with labeled parts including the vent, mouthpiece, yellow cap, and dose counter. The inhaler is shown from two angles, highlighting these components for user reference.*

FDA Label Image

Figure B (Fluticasone Propionate Salmeterol Inhalation Powde 14)

An instructional diagram showing the dose counter window of a metered powder inhaler for Fluticasone Propionate and Salmeterol. It illustrates two states: 'Inhaler Full' with 60 doses available and 'Inhaler Empty' indicating 0 doses remaining, with numbers displayed in the counter windows.*

FDA Label Image

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 15)

An instructional illustration showing a person attaching a yellow dose counter or safety cap to the mouthpiece of an inhaler. The image includes a directional arrow indicating the cap being flipped into place with a 'CLICK' sound, demonstrating how to secure the inhaler device.*

FDA Label Image

Figure D (Fluticasone Propionate Salmeterol Inhalation Powde 16)

Instructional illustration showing correct and incorrect methods for attaching the yellow dose counter to the inhaler device of Fluticasone Propionate and Salmeterol powder, metered for respiratory inhalation. The first image marked with a check shows the proper way to align and connect the dose counter, while the two images marked with an X demonstrate improper attachment methods.*

FDA Label Image

Breathe Out Image (Fluticasone Propionate Salmeterol Inhalation Powde 17)

An illustration showing a side profile of a human face with dots near the mouth, likely depicting aerosol or inhaled powder being released into the air. The image suggests inhalation or respiratory drug delivery, consistent with the product's route of administration.*

FDA Label Image

Figure F (Fluticasone Propionate Salmeterol Inhalation Powde 18)

An instructional illustration showing a person placing a respiratory inhaler device with a yellow base near their mouth, demonstrating the correct position for inhalation of Fluticasone Propionate and Salmeterol metered powder via oral respiratory route.*

FDA Label Image

Figure G (Fluticasone Propionate Salmeterol Inhalation Powde 19)

An illustration showing the mouthpiece of an inhaler device for Fluticasone Propionate and Salmeterol powder, metered for respiratory inhalation. The diagram highlights the vent area on the inhaler, with the mouthpiece cover shown in yellow.*

FDA Label Image

Salmeterol Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 2)

Chemical structure of the active ingredients Fluticasone Propionate and Salmeterol, showing a detailed molecular diagram with multiple hydroxyl groups and aromatic rings.*

FDA Label Image

Figure H (Fluticasone Propionate Salmeterol Inhalation Powde 20)

Instructional illustration showing a person holding a metered dose inhaler with one hand and opening or closing the yellow cap on the inhaler mouthpiece with the other hand. An arrow indicates the direction to flip the cap open. This diagram likely demonstrates proper handling or preparation of the inhaler for use.*

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 21)

FDA Label Image

Figure 1 (Fluticasone Propionate Salmeterol Inhalation Powde 3)

A comparison plot from Trial 201 and Trial 202 displaying differences from placebo with 95% confidence intervals for fluticasone propionate dry powder inhalers (FP DPI) and fluticasone propionate multidose dry powder inhalers (FP MDPI) at varying treatment doses in micrograms (mcg). The graph shows treatment effects on the y-axis and doses on the x-axis, indicating variability across different dosages and inhaler types.*

FDA Label Image

Figure 2 (Fluticasone Propionate Salmeterol Inhalation Powde 4)

A line graph showing baseline-adjusted FEV1 (mL) over a 12-hour time period for various formulations and doses of Fluticasone Propionate and Salmeterol, including FS MDPI 118 mcg at different dose levels and FP MDPI and FS DPI formulations. The x-axis represents time in hours, and the y-axis represents FEV1 change in milliliters.*

FDA Label Image

Figure 3 (Fluticasone Propionate Salmeterol Inhalation Powde 5)

A line graph depicting mean changes in FEV1 (forced expiratory volume in 1 second) over 12 weeks for different dosing groups of Fluticasone Propionate and Salmeterol (FS MDPI and FP MDPI) at strengths 113 mcg/14 mcg and 55 mcg/14 mcg, compared to placebo. The x-axis shows weeks 0 to 12, and the y-axis shows mean change in FEV1 in liters.*

FDA Label Image

Figure 4 (Fluticasone Propionate Salmeterol Inhalation Powde 6)

A line graph showing the mean change in FEV1 (liters) over 12 hours from baseline on Day 1 for different treatments: FS MDPI at 113 mcg/14 mcg and 55 mcg/14 mcg, FP MDPI at 113 mcg and 55 mcg, and placebo. The y-axis indicates mean change in FEV1 (L) and the x-axis indicates time in hours.*

FDA Label Image

Figure 5 (Fluticasone Propionate Salmeterol Inhalation Powde 7)

A line graph depicting the mean change in FEV1 (L) over 12 hours after Day 1 and Week 12 baselines. It compares five groups: FS MDPI 113 mcg/14 mcg, FS MDPI 55 mcg/14 mcg, FP MDPI 113 mcg, FP MDPI 55 mcg, and Placebo. The y-axis is mean change in FEV1, and the x-axis is time in hours.*

FDA Label Image

Figure 6 (Fluticasone Propionate Salmeterol Inhalation Powde 8)

A line graph showing mean change in FEV1 (L) over 12 weeks for different treatment groups including FS MDPI 232 mcg/14 mcg, FS MDPI 113 mcg/14 mcg, FP MDPI 232 mcg, FP MDPI 113 mcg, and placebo. The x-axis represents time in weeks and the y-axis shows the mean change in FEV1 in liters. Sample sizes for each group at selected time points are listed below the graph.*

FDA Label Image

Figure 7 (Fluticasone Propionate Salmeterol Inhalation Powde 9)

A line graph depicting mean change in FEV1 (L) over 12 hours after dosing, comparing FS MDI at 232 mcg/14 mcg and 113 mcg/14 mcg, FP MDI at 232 mcg and 113 mcg, and placebo. The x-axis represents time in hours, and the y-axis shows mean change in FEV1 in liters, illustrating differences in respiratory function over time among the treatment groups.*

FDA Label Image

Lbl500903271

Fluticasone Propionate and Salmeterol 113 mcg/14 mcg inhalation powder metered dose label from A-S Medication Solutions. The label shows storage instructions to keep the product below 30 degrees Celsius and indicates the package contains 60 metered inhalations with a total weight of 0.45 grams. The NDC number 50090-3271-0 is visible along with distribution details from A-S Medication Solutions, Libertyville, Illinois.*

FDA Label Image

Lbl500903272

Fluticasone Propionate and Salmeterol inhalation powder label with strength 55 mcg/14 mcg per inhalation. The packaging indicates 60 metered inhalations with a net weight of 0.45 g. It includes storage instructions to store at 59 to 77 degrees Fahrenheit and avoid exposure to extreme heat, cold, and humidity. Distributed by A-S Medication Solutions, Libertyville, IL.*

FDA Label Image

Label Image (Lbl500903387)

Fluticasone Propionate and Salmeterol inhalation powder carton by A-S Medication Solutions. The label shows the product name, strengths (e.g., 232 mcg/14 mcg per dose), dosage form as metered inhalation powder, 60 metered inhalations per container, and storage instructions to keep the product at 59 to 77 degrees Fahrenheit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.